Coherus BioSciences
CHRS

$1.72

5.77%

Market Cap: 197M

About: Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Employees: 306

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.31% less ownership

Funds ownership: 73.63% [Q4 2023] → 73.32% (-0.31%) [Q1 2024]

3% less call options, than puts

Call options by funds: $666K | Put options by funds: $684K

14% less funds holding

Funds holding: 155 [Q4 2023] → 134 (-21) [Q1 2024]

28% less capital invested

Capital invested by funds: $271M [Q4 2023] → $195M (-$75.3M) [Q1 2024]

31% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 55

49% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 43

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$7

307%

upside

Avg. target

$10.50

510%

upside

High target

$13

656%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Baird Colleen Kusy	365%upside $8	Outperform Maintained	1 Jul 2024
HC Wainwright & Co. Douglas Tsao	598%upside $12	Buy Reiterated	24 May 2024
Truist Securities Robyn Karnauskas	307%upside $7	Buy Maintained	13 May 2024
HC Wainwright & Co. Douglas Tsao	598%upside $12	Buy Maintained	10 May 2024
HC Wainwright & Co. Douglas Tsao	540%upside $11	Buy Maintained	20 Mar 2024

See Analyst Rankings

Financial journalist opinion

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus BioSciences, Inc. is relying on revenues from existing drugs and its developmental pipeline after selling off a major source of revenue in Cimerli. CHS-114, an anti-CCR8 antibody being developed by CHRS, is set to produce data at the ASCO 2024 Annual Meeting. Coherus BioSciences refers to Yusimry (a biosimilar Humira) as a non-core product, and could look to sell the drug, although revenues are growing.

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until June 26, 2024.

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer Rosh Dias - Chief Medical Officer Theresa LaVallee - Chief Development Officer Bryan McMichael - Interim Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Colleen Kusy - Baird Operator Ladies and gentlemen, thank you for standing by.

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.75 per share a year ago.

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

– New $38.7 million term loan with a May 2029 maturity – – $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® –

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

See News Rankings